Ocera Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
May 21, 2014 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today...
Ocera Reports First Quarter Financial Results
May 08, 2014 16:30 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 8, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its...
Ocera Therapeutics Announces Appointment of Gaurav Aggarwal, M.D., as Chief Business Officer
May 02, 2014 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D., has joined the Company as its Chief Business Officer.
"We are excited...
Ocera Therapeutics to Announce First Quarter Financial Results
April 29, 2014 08:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced...
Ocera Reports Fourth Quarter and Year-End 2013 Financial Results
March 13, 2014 16:30 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., March 13, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today...
Ocera Therapeutics to Announce Fourth Quarter and Year End Financial Results
March 04, 2014 00:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced...
Ocera Therapeutics to Present at the Cowen and Company 34th Annual Health Care Conference
February 26, 2014 16:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today...
Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy
January 08, 2014 16:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced enrollment of the first patient in its multi-center Phase 2b study, the "STOP-HE" or OCR002-HE209...
Ocera Therapeutics Announces Election of Wendell Wierenga to Board
December 24, 2013 13:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Dec. 24, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors.
"We are excited that Wendell...
Ocera Therapeutics and the Roche Group Enter Into Technology Transfer and License Agreement
December 17, 2013 16:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group,...